Expansion and Investment Delpharm Gaillard is actively expanding its manufacturing capacity with recent investments in Canada and France, including a $140M upgrade of the Boucherville facility and a €28M sterile line expansion in Tours. These developments indicate a focus on increasing production capabilities and serving larger clients, presenting opportunities to offer complementary manufacturing and tech solutions.

Strategic Partnerships The company has established high-profile collaborations with Pfizer, BioNTech, and Sandoz for COVID vaccine fill&finish and injectable product manufacturing, demonstrating a strong reputation in high-demand, regulated environments. This opens avenues to pitch specialized services, quality systems, and advanced manufacturing technologies to similar clients in the biotech and pharmaceutical sectors.

Recent Funding Growth With recent financing of $60M and substantial investments planned, Delpharm is expanding its financial stability and capacity for large-scale projects. Business partners offering capital equipment, facility management, or pharmaceutical-specific software could find prospects in supporting their growth initiatives.